CMT-DN Tiny Machines Working to Elucidate Mechanisms of Cerebrovascular Pathologies
- Coordinator
- University of Galway, Ireland
- Runs
- 1 January 2026 to 31 December 2029
- Status
- Running
- EU funding
- €4.2m
- Total cost
- —
- Partners
- 14 organisations in 8 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101227628
What the project is doing
In the project's own words, from its summary on CORDIS.
The CerebroMachinesTrain Doctoral Network (CMT-DN) seeks to go beyond the state-of-the-art of drug delivery systems by focusing on tiny machines (TMs) that can be engineered as stable formulation devices capable of: i) transporting the desired amount of therapeutic substance (drug) to a target area; ii) preserving its designed function under variable physiological parameters; iii) enhancing drug bioavailability; iv) preserving the healthy environment (cells, tissues, organs) with minimal to no side effects.
These TMs will require innovative engineering designs to face the complex brain environment in which they must perform as a first organ testing platform. CMT-DN aims to train and transform a young, talented generation of 14 researchers to PhD level and as future leaders in the state-of-the-art engineering of TMs and brain-on-chip devices (VRAINORG) for unravelling the mechanisms and improved treatment options underlying cerebrovascular pathologies.
The engineered TMs will be designed to work and tested against VRAINORG platforms, which are 3D non-animal technologies of vascularised brain organoids (healthy and disease models) incorporated within microphysiological systems (MPs). This innovative training programme will bring together a panel of academic and industry experts in TMs biomimetic therapeutic systems and brain MPs comprising five academic and four industry partner beneficiaries, consolidated through three academic and two industry-associated partners covering nine countries across Europe and beyond, including one US associated partner.
By employing these emerging non-animal technologies (i.e., vascularised brain-on-chip models), the resulting innovative therapeutic systems will benefit from facilitated clinical translation while reducing the high cost and time-consuming aspects of pre-clinical animal studies.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| University of Galway | Galway | Ireland | Coordinator |
| Ibidi GmbH | Planegg Martinsried | Germany | Participant |
| Technische Universitat Darmstadt | Darmstadt | Germany | Participant |
| Basque Center for Macromolecular Design and Engineering Polymat Fundazioa | Donostia San Sebastian | Spain | Participant |
| Universidad Del Pais Vasco/ Euskal Herriko Unibertsitatea | Leioa | Spain | Associatedpartner |
| Microfluidics Innovation Center | Paris | France | Participant |
| React4life SpA | Genova | Italy | Participant |
| Universita Degli Studi Di Trento | Trento | Italy | Participant |
| Universita' Degli Studi Di Milano-Bicocca | Milano | Italy | Associatedpartner |
| Life-Chip B.V. | Sappemeer | Netherlands | Associatedpartner |
| Mimetas BV | Leiden | Netherlands | Participant |
| Stichting Amsterdam Umc | Amsterdam | Netherlands | Associatedpartner |
| Institutul De Chimie Macromoleculara Petru Poni | Iasi | Romania | Participant |
| AxoSim Technologies LLC | New Orleans | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS